Secondary Progressive Multiple Sclerosis Drug Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global secondary progressive multiple sclerosis drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Secondary progressive MS (SPMS) is a form of MS that occurs after relapsing-remitting MS. The disease varies across individuals and does not occur in all the patients who priorly have RRMS. The major factor contributing to the growth of the market is the increasing prevalence of the disease across the globe.
According to the National Multiple Sclerosis Society (NMSS),
an estimated 50% of patients who are diagnosed with relapsing-remitting MS
(RRMS) would transition to secondary-progressive MS (SPMS) within 10 years.
Additionally, within 25 years, 90% of patients who are diagnosed with
relapsing-remitting MS (RRMS) would evolve to secondary-progressive MS (SPMS).
Hence, the rising prevalence of the disease is driving the demand for secondary
progressive multiple sclerosis drugs.
To Request a Sample of our Report on Secondary
Progressive Multiple Sclerosis Drug Market: https://www.omrglobal.com/request-sample/secondary-progressive-multiple-sclerosis-drug-market
Some major players operating in the market include Actelion
Ltd., Biogen Inc., and Novartis International AG, among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers & acquisitions,
geographical expansion, partnerships and collaborations, and new product
launches, to stay competitive in the market. For instance, in March 2019,
Novartis announced the approval of Mayzent (siponimod) from the FDA. It is an
oral drug used for the treatment of relapsing forms of multiple sclerosis,
including secondary progressive multiple sclerosis (SPMS) with active disease,
relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome
(CIS) in adults.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Actelion Ltd., Biogen Inc.,
and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Secondary Progressive Multiple Sclerosis Drug Market is
Available @ https://www.omrglobal.com/industry-reports/secondary-progressive-multiple-sclerosis-drug-market
Global Secondary Progressive Multiple Sclerosis Drug Market Report by
Segment
By Type
·
Inebilizumab
·
GLX-1112
·
DC-TAB
·
Etomoxir
·
IB-MS
·
Others
By Application
·
Hospital
·
Clinic
·
Others
Global Secondary Progressive Multiple Sclerosis Drug Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment